BUY TRANSDERMAL SCOP ONLINE
Transderm Scop belongs to a class of drugs called Antiemetic Agents.
It is not known if Transderm Scop is safe and effective in children.
What are the possible side effects of Transderm Scop?
Transderm Scop may cause serious side effects including:
- severe dizziness,
- extreme fear,
- unusual thoughts or behavior,
- convulsions (seizures),
- eye pain or redness,
- blurred vision,
- dilated pupils,
- decreased urination,
- painful or difficult urination,
- stomach pain,
- nausea, and
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Transderm Scop include:
- dry mouth,
- sore throat,
- blurred vision or other eye problems,
- confusion, and
- feeling agitated or irritable
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Transderm Scop. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The Transderm Scop® (scopolamine) transdermal system is a circular flat patch designed for continuous release of scopolamine following application to an area of intact skin on the head, behind the ear. Each system contains 1.5 mg of scopolamine base. Scopolamine is α -(hydroxymethyl) benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo [3.3.1.02,4 ] non-7-yl ester. The empirical formula is C17H21NO4 and its structural formula is:
Scopolamine is a viscous liquid that has a molecular weight of 303.35 and a pKa of 7.55-7.81. The Transderm Scop system is a film 0.2 mm thick and 2.5 cm², with four layers. Proceeding from the visible surface towards the surface attached to the skin, these layers are: (1) a backing layer of tan-colored, aluminized, polyester film; (2) a drug reservoir of scopolamine, light mineral oil, and polyisobutylene; (3) a microporous polypropylene membrane that controls the rate of delivery of scopolamine from the system to the skin surface; and (4) an adhesive formulation of mineral oil, polyisobutylene, and scopolamine. A protective peel strip of siliconized polyester, which covers the adhesive layer, is removed before the system is used. The inactive components, light mineral oil (12.4 mg) and polyisobutylene (11.4 mg), are not released from the system.
Cross section of the system: